REG - Hutchmed China Ltd - Notice of Results

HUTCHMED (China)Announcement

31/01/2023 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230131:nRSe2703Oa&default-theme=true

RNS Number : 2703O  Hutchmed (China) Limited  31 January 2023

HUTCHMED to Announce 2022 Final Results

 

Hong Kong, Shanghai & Florham Park, NJ - Tuesday, January 31, 2023:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year
ended December 31, 2022 on Tuesday, February 28, 2023 at 3:30 am Eastern
Standard Time (EST) / 8:30 am Greenwich Mean Time (GMT) / 4:30 pm Hong Kong
Time (HKT).

 

Analysts and investors are invited to join a conference call and audio webcast
presentation with Q&A, conducted by HUTCHMED management.

 

The conference call and audio webcast will take place at 8:00 am EST / 1:00 pm
GMT / 9:00 pm HKT on Tuesday, February 28, 2023 and will be webcast live via
the company website at www.hutch-med.com/event/
(https://www.hutch-med.com/event/) . The presentation will be available for
downloading before the conference call begins. Details of the conference call
dial-in will be provided in the financial results announcement and on the
company website.  A replay will also be available on the website shortly
after the event.

 

 

About HUTCHMED
 
HUTCHMED (Nasdaq/AІM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Іt has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit:
www.hutch‑med.com (https://www.hutch-med.com/)
 or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/)
.

 

 

CONTACTS

 

 Investor Enquiries
 Mark Lee, Senior Vice President         +852 2121 8200
 Annie Cheng, Vice President             +1 (973) 567 3786

 Media Enquiries
 Americas - Brad Miles, Solebury Trout   +1 (917) 570 7340 (Mobile) / bmiles@s (mailto:bmiles@soleburystrat.com)
                                         oleburystrat (mailto:bmiles@soleburystrat.com) .com
                                         (mailto:bmiles@soleburystrat.com)
 Europe - Ben Atwell / Alex Shaw,        +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

FTI Consulting                         +44 7779 545 055 (Mobile)
                                         HUTCHMED@fticonsulting.com (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi,                         +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Brunswick                              (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,       +44 (20) 7886 2500

Panmure Gordon (UK) Limited

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFBLFXXFLBBBL